TY - JOUR
AU - K. N. Tormohlen
AU - M. D. Eisenberg
AU - M. I. Fingerhood
AU - J. Yu
AU - A. D. McCourt
AU - E. A. Stuart
AU - L. Rutkow
AU - L. Quintero
AU - S. A. White
AU - E. E. McGinty
A1 - 
AB - OBJECTIVE: The authors examined trends in opioid use disorder treatment and in-person and telehealth modalities before and after COVID-19 pandemic onset among patients who had received treatment prepandemic. METHODS: The sample included 13,113 adults with commercial insurance or Medicare Advantage and receiving opioid use disorder treatment between March 2018 and February 2019. Trends in opioid use disorder outpatient treatment, treatment with medications for opioid use disorder (MOUD), and in-person and telehealth modalities were examined 1 year before pandemic onset and 2 years after (March 2019-February 2022). RESULTS: From March 2019 to February 2022, the proportion of patients with opioid use disorder outpatient and MOUD visits declined by 2.8 and 0.3 percentage points, respectively. Prepandemic, 98.6% of outpatient visits were in person; after pandemic onset, at least 34.9% of patients received outpatient care via telehealth. CONCLUSIONS: Disruptions in opioid use disorder outpatient and MOUD treatments were marginal during the pandemic, possibly because of increased telehealth utilization.
AD - Departments of Health Policy and Management (Tormohlen, Eisenberg, McCourt, Stuart, Rutkow, White) and Mental Health (Fingerhood, Stuart), Johns Hopkins Bloomberg School of Public Health, Baltimore; Department of Population Health Sciences, Division of Health Policy and Economics, Weill Cornell Medicine, New York City (Yu, McGinty); Johns Hopkins Carey Business School, Washington, D.C. (Quintero).
AN - 37461819
BT - Psychiatr Serv
C5 - Opioids & Substance Use; HIT & Telehealth; Financing & Sustainability
CP - 1
DA - Jan 1
DO - 10.1176/appi.ps.20230102
DP - NLM
ET - 20230718
IS - 1
JF - Psychiatr Serv
LA - eng
N2 - OBJECTIVE: The authors examined trends in opioid use disorder treatment and in-person and telehealth modalities before and after COVID-19 pandemic onset among patients who had received treatment prepandemic. METHODS: The sample included 13,113 adults with commercial insurance or Medicare Advantage and receiving opioid use disorder treatment between March 2018 and February 2019. Trends in opioid use disorder outpatient treatment, treatment with medications for opioid use disorder (MOUD), and in-person and telehealth modalities were examined 1 year before pandemic onset and 2 years after (March 2019-February 2022). RESULTS: From March 2019 to February 2022, the proportion of patients with opioid use disorder outpatient and MOUD visits declined by 2.8 and 0.3 percentage points, respectively. Prepandemic, 98.6% of outpatient visits were in person; after pandemic onset, at least 34.9% of patients received outpatient care via telehealth. CONCLUSIONS: Disruptions in opioid use disorder outpatient and MOUD treatments were marginal during the pandemic, possibly because of increased telehealth utilization.
PY - 2024
SN - 1075-2730
SP - 72
EP - 75+
ST - Trends in Opioid Use Disorder Outpatient Treatment and Telehealth Utilization Before and During the COVID-19 Pandemic
T1 - Trends in Opioid Use Disorder Outpatient Treatment and Telehealth Utilization Before and During the COVID-19 Pandemic
T2 - Psychiatr Serv
TI - Trends in Opioid Use Disorder Outpatient Treatment and Telehealth Utilization Before and During the COVID-19 Pandemic
U1 - Opioids & Substance Use; HIT & Telehealth; Financing & Sustainability
U3 - 10.1176/appi.ps.20230102
VL - 75
VO - 1075-2730
Y1 - 2024
ER -